中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
15期
2329-2330,2331
,共3页
糖尿病神经病变%周围神经系统疾病%度洛西汀%加巴喷丁
糖尿病神經病變%週圍神經繫統疾病%度洛西汀%加巴噴丁
당뇨병신경병변%주위신경계통질병%도락서정%가파분정
Diabetic neuropathies%Peripheral nervous system diseases%Duloxetine%Gabapentin
目的：比较度洛西汀与加巴喷丁治疗糖尿病周围神经炎的疗效与安全性。方法将135例糖尿病周围神经炎患者按随机数字表法分为观察组（71例）和对照组（64例），所有患者根据糖尿病治疗原则进行降血糖治疗。此外，观察组患者接受口服度洛西汀治疗，对照组患者接受口服加巴喷丁治疗。在治疗前以及治疗后第1、2、4周末采用视觉模拟评分法（VAS）、健康调查简易量表（SF-36）对患者进行疼痛评分并记录患者治疗过程中的不良反应。结果（1）与治疗前比较，两组治疗后第1、2、4周末的VAS评分、SF-36评分均显著下降（均P＜0．05），但两组相同时间点的VAS评分、SF-36评分差异均无统计学意义（均P＞0．05）。（2）观察组口干、嗜睡、乏力、眩晕等不良反应发生率显著低于对照组（18．31％比34．38％，4．23％比26．56％，0.00％比23．44％，0．00％比15．63％，χ2＝4．059、13．308、4．059、4．059，均P＜0．05），两组恶心、心悸、腹泻等不良反应发生率相比差异均无统计学意义（均P＞0．05）。结论度洛西汀与加巴喷丁治疗糖尿病周围神经炎的疗效相当，但是度洛西汀的安全性更好。
目的：比較度洛西汀與加巴噴丁治療糖尿病週圍神經炎的療效與安全性。方法將135例糖尿病週圍神經炎患者按隨機數字錶法分為觀察組（71例）和對照組（64例），所有患者根據糖尿病治療原則進行降血糖治療。此外，觀察組患者接受口服度洛西汀治療，對照組患者接受口服加巴噴丁治療。在治療前以及治療後第1、2、4週末採用視覺模擬評分法（VAS）、健康調查簡易量錶（SF-36）對患者進行疼痛評分併記錄患者治療過程中的不良反應。結果（1）與治療前比較，兩組治療後第1、2、4週末的VAS評分、SF-36評分均顯著下降（均P＜0．05），但兩組相同時間點的VAS評分、SF-36評分差異均無統計學意義（均P＞0．05）。（2）觀察組口榦、嗜睡、乏力、眩暈等不良反應髮生率顯著低于對照組（18．31％比34．38％，4．23％比26．56％，0.00％比23．44％，0．00％比15．63％，χ2＝4．059、13．308、4．059、4．059，均P＜0．05），兩組噁心、心悸、腹瀉等不良反應髮生率相比差異均無統計學意義（均P＞0．05）。結論度洛西汀與加巴噴丁治療糖尿病週圍神經炎的療效相噹，但是度洛西汀的安全性更好。
목적：비교도락서정여가파분정치료당뇨병주위신경염적료효여안전성。방법장135례당뇨병주위신경염환자안수궤수자표법분위관찰조（71례）화대조조（64례），소유환자근거당뇨병치료원칙진행강혈당치료。차외，관찰조환자접수구복도락서정치료，대조조환자접수구복가파분정치료。재치료전이급치료후제1、2、4주말채용시각모의평분법（VAS）、건강조사간역량표（SF-36）대환자진행동통평분병기록환자치료과정중적불량반응。결과（1）여치료전비교，량조치료후제1、2、4주말적VAS평분、SF-36평분균현저하강（균P＜0．05），단량조상동시간점적VAS평분、SF-36평분차이균무통계학의의（균P＞0．05）。（2）관찰조구간、기수、핍력、현훈등불량반응발생솔현저저우대조조（18．31％비34．38％，4．23％비26．56％，0.00％비23．44％，0．00％비15．63％，χ2＝4．059、13．308、4．059、4．059，균P＜0．05），량조악심、심계、복사등불량반응발생솔상비차이균무통계학의의（균P＞0．05）。결론도락서정여가파분정치료당뇨병주위신경염적료효상당，단시도락서정적안전성경호。
Objective To compare the efficacy and safety of duloxetine and gabapentin in the treatment of diabetic peripheral neuritis .Methods 135 patients with diabetic peripheral neuritis were divided into the observation group(71 cases) and the control group (64 cases) according to random number table method ,and all patients received hypoglycemic therapy based on diabetes treatment principle .Furthermore,the observation group received oral duloxe-tine,while the control group was given oral gabapentin .The pain scores of all patients were evaluated using visual ana-log scale(VAS) and medical outcomes study (SF-36),and the adverse reactions were recorded during treatment . Results (1) Compared with before treatment ,both VAS scores and SF-36 scores in observation group and control group declined significantly at the end of 1st,2nd,4th week after treatment(all P<0.05),while there were no statis-tically significant differences in VAS scores and SF-36 scores between the two groups at the same time point ( all P>0.05).(2)The incidence rates of dry mouth ,drowsiness,fatigue and dizziness in observation group were significantly lower than those in control group (18.31% vs.34.38%,4.23% vs.26.56%,0.00% vs.23.44%,0.00% vs. 15.63%,χ2 =4.059,13.308,4.059,4.059,all P<0.05),while there were no statistically significant differences in incidence rates of nausea ,diarrhea and flustered between the two groups (all P<0.05).Conclusion The duloxetine and gabapentin in the treatment of diabetic peripheral neuritis have similar efficacy , but the duloxetine has better security.
